InsiderSignal.AI

InsiderSignal.ai

ADMA - Adma Biologics, Inc.

Insider Sale by Grossman Adam S (Pres, CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

2 days ago, Grossman Adam S, serving as Pres, CEO at Adma Biologics, Inc. (ADMA), sold 21,000 shares at $15.16 per share, for a total transaction value of $318,360.00. Following this transaction, Grossman Adam S now holds 3,837,160 shares of ADMA.

This sale represents a 1.00% decrease in Grossman Adam S's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Monday, March 16, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, March 17, 2026, 1 day after the trade was made.

Adma Biologics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Grossman Adam S

Pres, CEO

Adam S. Grossman is the Founder, President, Chief Executive Officer, and Director of ADMA Biologics, Inc. (NASDAQ: ADMA), a biopharmaceutical company specializing in plasma-derived biologics for immune-compromised patients.[[1]](https://www.clay.com/dossier/adma-biologics-ceo)[[3]](https://www.admabiologics.com/about/board-of-directors)[[5]](https://www.admabiologics.com/about/senior-leadership-team) He co-founded the company in 2007, initially serving as President and Chief Operating Officer until October 2011, when he assumed his current roles, leading ADMA through key milestones including its 2013 public listing, FDA approvals for products like ASCENIV™, the 2017 acquisition of Biotest Therapy Business Unit, and over $1.2 billion in financing.[[1]](https://www.clay.com/dossier/adma-biologics-ceo)[[3]](https://www.admabiologics.com/about/board-of-directors)[[5]](https://www.admabiologics.com/about/senior-leadership-team) Grossman recently sold 21,000 shares on November 19, 2025, for $336,000, while exercising options for 15,000 shares, retaining significant holdings directly and indirectly.[[4]](https://www.investing.com/news/insider-trading-news/adma-biologics-adma-ceo-grossman-sells-336k-in-shares-93CH-4374055) With over 25 years in the blood and plasma industry, Grossman's prior roles include Executive Vice President at National Hospital Specialties (2005-2007) and GenesisBPS (2003-2005), various positions at MedImmune, Inc. (2000-2003), and the American Red Cross (1998-2000).[[1]](https://www.clay.com/dossier/adma-biologics-ceo)[[2]](https://www.comparably.com/companies/adma-biologics/ceo-rating)[[3]](https://www.admabiologics.com/about/board-of-directors) He holds a B.S. in Business Administration, specializing in International Business and Marketing, from American University, and serves as Chair of the North America Board of Directors of the Plasma Protein Therapeutics Association since September 2023.[[1]](https://www.clay.com/dossier/adma-biologics-ceo)[[3]](https://www.admabiologics.com/about/board-of-directors) Son of Vice Chairman and co-founder Dr. Jerrold B. Grossman, he has driven ADMA's transformation into a vertically integrated manufacturer.[[3]](https://www.admabiologics.com/about/board-of-directors)

View full insider profile →

Trade Price

$15.16

Quantity

21,000

Total Value

$318,360.00

Shares Owned

3,837,160

Trade Date

Monday, March 16, 2026

2 days ago

SEC Filing Date

Tuesday, March 17, 2026

Filed 1 day after trade

HEALTHCAREBIOTECHNOLOGY

About Adma Biologics, Inc.

Company Overview

No company information available
View news mentioning ADMA

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4873251

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime